Archive for August, 2010

Emergent BioSolutions Hosts Symposium for Biomedical Research Scholars

ROCKVILLE, Md., Aug 24, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today hosted “Looking Beyond the Bench,” a symposium organized for doctoral students enrolled in the NIH-Oxford-Cambridge Scholars Program. The symposium featured Emergent executives, who, based on their extensive experience in the biopharmaceutical industry, [...]

August 30, 2010  Tags: , , , , , , ,   Posted in: Anthrax vaccines, Biosolutions, Business, El-Hibri Peace Education Prize, Emergent BioSolutions, Infectious disease, Scholars Program, fuad el-hibri  No Comments

Colman McCarthy to Receive 2010 EL-HIBRI Peace Education Prize

August  17,  2010  — The El-Hibri Charitable Foundation announced today that prominent peace educator, nationally renowned columnist and accomplished author Colman McCarthy has been selected as the recipient of the  2010 El-Hibri Peace Education Prize. The Prize, which carries a [...]

August 23, 2010  Tags: , , , , , , ,   Posted in: CEO, El-Hibri, El-Hibri Peace Education Prize, Emergent BioSolutions, Peace Education, fuad el-hibri  No Comments

Emergent BioSolutions to Acquire Trubion Pharmaceuticals

Trubion provides promising clinical-stage therapeutic candidates in the targeted disease areas of oncology and autoimmunity
Trubion offers novel, protein therapeutic platforms and scientific expertise for developing innovative therapeutic candidates
Transaction leverages large pharma partnerships to provide sales and marketing infrastructureidates
Emergent reaffirms 2010 guidance for revenues and net income

ROCKVILLE, Md., Aug 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. [...]

August 19, 2010  Tags: , , , , , , ,   Posted in: Africa, Anthrax vaccines, Biosolutions, Emergent BioSolutions, Health Care, Management, Research and development, Share, Trubion Pharmaceuticals, fuad el-hibri  No Comments

Emergent Revises Upward 2010 Financial Forecast

Company anticipates total revenues of $275 to $300 million and net income of $40 to $50 million
ROCKVILLE, MD, July 20, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it is revising upwards its 2010 annual guidance to now reflect anticipated total revenues of $275 to $300 million and net income of [...]

August 3, 2010  Tags: , , , , , , ,   Posted in: Anthrax vaccines, Biothrax, Emergent BioSolutions, Health Care, fuad el-hibri  No Comments